Citywire for Financial Professionals

Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2575.00

Share Price

N/A

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 39.07%
Worldwide Healthcare (Ordinary Share) NAV 29.19%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2585.0 0.4% 2575.00 2560.00
22 May
104% 0.87%

Discrete performance % over

Fund / BenchmarkJun '15
May '16
Jun '16
May '17
Jun '17
May '18
Worldwide Healthcare (Ordinary Share) Price-8.7338.3210.16
Worldwide Healthcare (Ordinary Share) NAV-7.8225.2911.86

Discrete performance over

Discrete Performance

Top 10 Holdings

Alexion Pharmaceuticals, Inc. 4.10%
Merck & Co. Inc. 4.00%
Boston Scientific, Inc. 3.90%
Regeneron Pharmaceuticals, Inc. 3.70%
Novo-Nordisk 3.50%
Bristol-Myers Squibb Company 3.00%
Wright Medical Group, Inc. 2.90%
VERTEX MILESTONE MONETIZATION (UNQUOTED, 2.90%
Celgene Corporation 2.70%
Biogen Idec Inc., 2.70%

Sectors weighting

Pharmaceuticals 96.90%
General Equity 3.10%
Net Current Assets 0.00%

Regional weighting

North America Region 66.00%
Europe Developed ex-UK 19.00%
Japan 8.00%
Asia exc Japan 5.00%
Other Countries 1.00%
Fixed Interest 1.00%
Cash/Cash Equivalent 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price N/A
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 50
  • Market Capital (£M) 1291.70
  • Gross Assets (£M) 1343.98
  • Net Assets (£M) 1286.83
  • TER (%) 0.91
  • Historic Dividend Yield (%) 0.87
  • Last AGM 21 Sep 2017
  • Next AGM 21 Sep 2018
  • Last Annual Report Date 14 Jul 2017
  • Next due Report Date 31 Mar 2018
  • Next due Report Type A/R
  • Objective:

  • To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, 0.15% in excess of 500 million and up to 1 billion, 0.125% in excess of 1 billion to 1.5 billion, and over 1.5 billion 0.075%, plus a fixed amount equal to £ 57,500 p.a. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.

Sorry, this link is not
quite ready yet